

ABIOMED INC  
Form 8-K  
March 28, 2008  
**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report: March 28, 2008

**(Date of earliest event reported)**

**ABIOMED, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware** **04-2743260**  
**(State or other Jurisdiction of Incorporation) (IRS Employer Identification Number)**  
**0-20584**  
**(Commission File Number)**

**22 Cherry Hill Drive**

**Danvers, MA 01923**  
**(Address of Principal Executive Offices, including Zip Code)**  
**(978) 646-1400**  
**(Registrant's Telephone Number, including Area Code)**

**Not Applicable**  
**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---



**Item 8.01 Other Events.**

On March 28, 2008, we issued a press release announcing an update on our submission to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of our Impella 2.5 product. A copy of the press release is set forth as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Number	Title
99.1	Press Release dated March 28, 2008

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Abiomed, Inc.

By: /s/ Daniel J. Sutherby  
Daniel J. Sutherby  
Chief Financial Officer

Date: March  
28,  
2008